Higher-risk myelodysplastic syndrome in an elderly patient: Long-term partial remission with low-dose prednisone, G-CSF, and epoetin alfa

Abstract

Currently, most patients with higher-risk MDS are treated with 5-azacitidine or decitabine. These agents are toxic. The treatment described here is safe, devoid of toxicity, fosters improved quality of life, and helps reduce transfusion requirements.

Keywords: G‐CSF; erythropoietin (EPO); higher‐risk; myelodysplastic syndrome; prednisone.